PL1697306T3 - Selektywne modulatory receptorów aktywowanych przez proliferatory peroksysomów - Google Patents

Selektywne modulatory receptorów aktywowanych przez proliferatory peroksysomów

Info

Publication number
PL1697306T3
PL1697306T3 PL04811083T PL04811083T PL1697306T3 PL 1697306 T3 PL1697306 T3 PL 1697306T3 PL 04811083 T PL04811083 T PL 04811083T PL 04811083 T PL04811083 T PL 04811083T PL 1697306 T3 PL1697306 T3 PL 1697306T3
Authority
PL
Poland
Prior art keywords
activated receptor
peroxisome proliferator
proliferator activated
receptor modulators
syndrome
Prior art date
Application number
PL04811083T
Other languages
English (en)
Inventor
Rafael Ferritto-Crespo
Finger Maria Delores Martin-Ortega
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PL1697306T3 publication Critical patent/PL1697306T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/18—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/18—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides
    • C07C235/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/18—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides
    • C07C235/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Liquid Crystal Substances (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
PL04811083T 2003-12-15 2004-12-08 Selektywne modulatory receptorów aktywowanych przez proliferatory peroksysomów PL1697306T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP03380288 2003-12-15
US55063604P 2004-03-05 2004-03-05
EP04811083A EP1697306B1 (en) 2003-12-15 2004-12-08 Selective peroxisome proliferator activated receptor modulators
PCT/US2004/038232 WO2005061441A1 (en) 2003-12-15 2004-12-08 Selective peroxisome proliferator activated receptor modulators

Publications (1)

Publication Number Publication Date
PL1697306T3 true PL1697306T3 (pl) 2007-11-30

Family

ID=34712592

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04811083T PL1697306T3 (pl) 2003-12-15 2004-12-08 Selektywne modulatory receptorów aktywowanych przez proliferatory peroksysomów

Country Status (25)

Country Link
US (1) US7321056B2 (pl)
EP (1) EP1697306B1 (pl)
JP (1) JP2007516267A (pl)
KR (1) KR100806004B1 (pl)
CN (1) CN1886364A (pl)
AT (1) ATE368026T1 (pl)
AU (1) AU2004303793A1 (pl)
BR (1) BRPI0417401A (pl)
CA (1) CA2549008A1 (pl)
CY (1) CY1106846T1 (pl)
DE (1) DE602004007825T2 (pl)
DK (1) DK1697306T3 (pl)
EA (1) EA009023B1 (pl)
EC (1) ECSP066639A (pl)
ES (1) ES2289589T3 (pl)
HR (1) HRP20070422T3 (pl)
IL (1) IL175997A0 (pl)
MA (1) MA28399B1 (pl)
MX (1) MXPA06006829A (pl)
NO (1) NO20063261L (pl)
PL (1) PL1697306T3 (pl)
PT (1) PT1697306E (pl)
SI (1) SI1697306T1 (pl)
WO (1) WO2005061441A1 (pl)
ZA (1) ZA200604834B (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013049621A1 (en) * 2011-09-29 2013-04-04 The Board Of Regents Of The University Of Oklahoma Ophthalmic compositions comprising ppar-alpha agonists and methods of production and use thereof
CN106310173A (zh) * 2016-08-24 2017-01-11 厦门三川利生物科技有限公司 含过氧化物酶体增殖物激活受体多维果酸醇及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
WO2000061582A1 (en) * 1999-04-08 2000-10-19 Sankyo Company, Limited Substituted fused imidazole derivatives
AU2002222552A1 (en) * 2000-11-29 2002-06-11 Kyorin Pharmaceutical Co. Ltd. Substituted carboxylic acid derivatives
WO2002083616A1 (en) * 2001-04-10 2002-10-24 Sankyo Company, Limited α-SUBSTITUTED φ-ARYLFATTY ACID DERIVATIVE
SE0104334D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
GB0314079D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
JP2005529975A (ja) * 2002-06-19 2005-10-06 イーライ・リリー・アンド・カンパニー アミドリンカーペルオキシソーム増殖因子活性化受容体調節因子

Also Published As

Publication number Publication date
IL175997A0 (en) 2006-10-05
KR20060121192A (ko) 2006-11-28
JP2007516267A (ja) 2007-06-21
US7321056B2 (en) 2008-01-22
HRP20070422T3 (en) 2007-11-30
CA2549008A1 (en) 2005-07-07
CY1106846T1 (el) 2012-05-23
CN1886364A (zh) 2006-12-27
ECSP066639A (es) 2006-10-25
AU2004303793A1 (en) 2005-07-07
ES2289589T3 (es) 2008-02-01
BRPI0417401A (pt) 2007-05-08
DE602004007825D1 (de) 2007-09-06
ATE368026T1 (de) 2007-08-15
DK1697306T3 (da) 2007-11-12
NO20063261L (no) 2006-09-06
EA200601159A1 (ru) 2006-10-27
MA28399B1 (fr) 2007-01-02
EP1697306A1 (en) 2006-09-06
SI1697306T1 (sl) 2008-02-29
US20070066683A1 (en) 2007-03-22
EP1697306B1 (en) 2007-07-25
KR100806004B1 (ko) 2008-02-26
EA009023B1 (ru) 2007-10-26
MXPA06006829A (es) 2006-08-23
DE602004007825T2 (de) 2008-04-17
HK1097406A1 (en) 2007-06-22
ZA200604834B (en) 2007-11-28
PT1697306E (pt) 2007-10-19
WO2005061441A1 (en) 2005-07-07

Similar Documents

Publication Publication Date Title
DE602004011985D1 (de) Modulatoren des peroxisomproliferatoraktivierten rezeptors
MXPA05008581A (es) Derivados de sulfonamida como moduladores de ppar.
IL159002A0 (en) Modulators of peroxisome proliferator activated receptors (ppar)
PL1853266T3 (pl) 2S,4R ketokonazol do leczenia cukrzycy, zespołu metabolicznego i innych schorzeń
NO20032861L (no) Heteroarylurea nevropeptid Y Y5-reseptorantagonister
NO20076060L (no) Piperidin-4-yl-amidderivater og deres anvendelse som SST-reseptor subtype 5-antagonister
ATE539743T1 (de) Verfahren zur prävention und behandlung von ppar- vermittelten zuständen mit macelignan
MXPA05001712A (es) Bifenilcarboxamidas sustituidas con n-aril piperidina como inhibidores de la secrecion de apolipoproteina b.
EA200601295A1 (ru) Производные 1,3-диоксана и их аналоги, применимые для лечения i.a. ожирения и диабета
ATE399546T1 (de) Cycloalkyl-lactam-derivate als inhibitoren von 11-beta-hydroxysteroiddehydrogenase 1
ATE401073T1 (de) Cycloalkyl-lactam-derivate als inhibitoren von 11-beta-hydroxysteroiddehydrogenase 1
ATE424821T1 (de) Pyrrolopyridin-2-karbonsäureamide
WO2004037776A3 (en) Novel compounds and their use as prar-modulators
IL175997A0 (en) Selective peroxisome proliferator activated receptor modulators
UA83265C2 (ru) Селективные модуляторы рецепторов, которые активируются пролифераторами пероксисом
MXPA06011513A (es) Derivados de indeno y proceso para la preparacion de los mismos.
DK1569904T3 (da) Substituerede arylalkansyrederivater som PPAR pan-agonister med kraftig antihyperglykæmisk og antihyperlipidæmisk aktivitet
WO2005049589A3 (en) Heterocyclic compounds for the treatment of hyperlipidemia, diabetes, obesity and similar diseases